Analysts Set Maplight Therapeutics, Inc. (NASDAQ:MPLT) PT at $31.00

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have earned an average rating of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $31.00.

A number of brokerages have issued reports on MPLT. Stifel Nicolaus assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 price objective for the company. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Leerink Partners initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “outperform” rating and a $30.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target for the company.

Maplight Therapeutics Stock Down 0.7%

NASDAQ:MPLT opened at $17.77 on Thursday. The stock has a 50-day simple moving average of $18.20. The stock has a market cap of $806.22 million and a P/E ratio of -0.48. Maplight Therapeutics has a 1-year low of $12.24 and a 1-year high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Insider Transactions at Maplight Therapeutics

In other news, Director Robert C. Malenka sold 21,262 shares of the firm’s stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $18.55, for a total transaction of $394,410.10. Following the sale, the director owned 371,885 shares of the company’s stock, valued at $6,898,466.75. This trade represents a 5.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders have sold 41,438 shares of company stock worth $762,687.

Institutional Investors Weigh In On Maplight Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth $53,000. Deutsche Bank AG bought a new stake in shares of Maplight Therapeutics during the 4th quarter valued at about $210,000. Nuveen LLC purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at about $355,000. TD Asset Management Inc bought a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $649,000. Finally, Seven Grand Managers LLC bought a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $1,756,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.